NCT05712096View on ClinicalTrials.gov

eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services

CompletedOBSERVATIONAL

Enrollment

4,000

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions

SARS-CoV-2COVID-19

Interventions

DRUG

EVUSHELD

EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)

Trial Locations (1)

Unknown

Research Site, Ramat Gan

Sponsors

Lead Sponsor

Collaborators (1)

Clalit Health Services

All Listed Sponsors

collaborator

Clalit Health Services

OTHER

lead

AstraZeneca

INDUSTRY